Resveratrol (RSV), a non-flavonoid polyphenol found in grapes and grape products such as red wine, exerts an antioxidant action with reported cancer preventive properties (Kris-Etherton et al., 2002). RSV also has anti-inflammatory, anticancer, and anti-neurodegenerative effects (Piotrowska et al., 2012). The role of RSV as an immune response modulator was demonstrated in both in vitro and in vivo studies, where it reversed immune senescence in older rats, reduced inflammatory responses in rodents, and improved immunological activity against cancer cells (Malaguarnera, 2019). RSV was shown to be involved in the activation of macrophages, T cells, and natural killer cells, as well as in the suppression processes of CD4⁺ CD25⁺ regulatory T cells (Yang et al., 2008; Svajger and Jeras, 2012). All these effects are due to its ability to remove ROS, inhibit cyclooxygenase (COX), and trigger anti-inflammatory pathways via SIRT1 activation (Miceli et al., 2014; Malaguarnera, 2019). Activated SIRT1 interrupts TLR4/NF-κB/STAT axis, reduces cytokine production by inactivated immune cells, and inhibits pro-inflammatory factors derived from macrophages/mast cells, such as platelet-activating factor and TNF-α (Capiralla et al., 2012).

RSV-SIRT1 interaction modifies SIRT1 structure and promotes binding activity with its substrates including p65/RelA (Yeung et al., 2004), a component of the NF-κB complex, which regulates activation of leukocytes and inflammatory cytokines. SIRT1 activated by RSV inhibits acetylation of RelA by reducing the expression of inflammatory factors such as TNF-α, IL-1β, IL-6, metalloprotease (MMP)-1, MMP-3, and NF-κB-mediated Cox-2 (Malaguarnera, 2019). AMP activated protein kinase (AMPK) is also a target of RSV, as it controls SIRT1 activity via regulation of cellular levels of NAD⁺, thus acting as an energy sensor (Price et al., 2012). Cyclic adenosine monophosphate (cAMP) levels activate protein kinase A, resulting in phosphorylation and activation of SIRT1 (Wan et al., 2016). Activated SIRT1 catalyzes the deacetylation and activation of PGC-1α, thereby promoting beneficial effects in the metabolism (Ren et al., 2019).

In different organisms (S. cerevisiae, C. elegans, and D. melanogaster) expressing SIRT1 (or its homologous genes), RSV treatment is able to extend life span. In mammalians, RSV administration can improve SIRT1-dependent cellular processes such as axonal protection (Araki et al., 2004), fat mobilization (Chaplin et al., 2018), and inhibition of NF-κB-dependent transcription (Yeung et al., 2019); these effects are abolished in SIRT1 knockdown models. Numerous studies investigated the beneficial effects of RSV in cardiovascular diseases including hypertension (Theodotou et al., 2017), cardiac ischemia (Fourny et al., 2019), and atherosclerosis (Chassot et al., 2018). RSV has an effect on blood vessels, reduces inflammation, and prevents thrombus formation and platelet oxidation (Zordoky et al., 2015). It can also reduce cardiac dysfunction, oxidative stress, fibrosis, and apoptosis in the heart (Gupta et al., 2014; Yamagata, 2019). In addition, RSV was found to improve heart and kidney damage in rats (Li et al., 2020a). The protective effect of RSV is associated with an increase in SIRT1 activity, which deacetylates FOXO1 and activates MnSOD downstream. RSV-induced MnSOD also reduces oxidative stress (Li et al., 2020a). A recent in vitro study showed that RSV reduces hypoxia-induced apoptosis in H9C2 cells through activation of SIRT1/miR-30d-5p/NF-κB axis (Han et al., 2020). RSV treatment decreased cortical and hippocampal malondialdehyde levels while increasing SOD activity and SIRT1 expression in a diabetic rat model (Ma et al., 2019).

RSV was shown to activate SIRT1 and improve endothelial function in obese mice via upregulation of PPARδ expression/activity in PPARδ mutant mice (Cheang et al., 2019). It had previously been observed that Akt activation together with PPARδ is involved in vascularization of db/db mice (Tian et al., 2012); RSV was subsequently reported to increase phosphorylation of Akt and transcriptional activity of PPARδ in the aorta of wild-type mice, thus supporting the hypothesis of SIRT1-PPARδ interaction, and to strongly decrease LPC-induced mitochondrial ROS in the aortic endothelium of C57BL/6 mice (Cheang et al., 2019). Taken together, these findings highlight the beneficial effects of RSV against oxidative stress, which is involved in major pathologies such as heart and metabolic disorders. Although RSV is beneficial in many contexts, its pleiotropic actions need to be better studied in order to understand which of its described activities are directly due to SIRT1 modulation and whether this effect is always direct.

Because of the pleiotropic actions of RSV, clinical trials are currently testing its therapeutic potential in a wide range of human diseases. However, of all the mechanisms described in in vitro and in vivo studies, only a few have been confirmed in humans, such as gene and protein regulation in blood or muscle cells, and Akt signaling pathways (Ghanim et al., 2010; Brasnyo et al., 2011). Many clinical studies conducted in healthy patients and volunteers using both high and low doses of RSV highlight its potential cardioprotective benefit through improvement of endothelial function, inflammatory markers, and glucose metabolism. Nevertheless, the mechanisms of action are not yet well defined. Despite clinical evidence of its effects, the poor bioavailability and rapid metabolism of RSV severely limit the potential use of this molecule in the clinic. Future scientific research should focus on identifying actual metabolites or mediators of these observed effects.

To date, 165 clinical trials have tested the efficacy, safety, and pharmacokinetics of RSV in the prevention and treatment of 32 different pathological conditions (www.clinical.trials.gov). Restricting the search to interventional phase 1/2/3/4 studies (completed and terminated clinical trials), 55 addressed the ability of RSV to improve the pathological conditions of patients affected by several diseases. Most of these studies tested RSV-mediated effects in central nervous system disorders (Friedreich ataxia, Alzheimer’s disease, Parkinson’s disease), metabolic disorders [T2D, insulin resistance, dyslipidemia, hypercholesterolemia, metabolic syndrome X, non-alcoholic fatty liver disease (NAFLD)]. A phase 1 clinical trial (NCT01640197) tested the effects of chronic resveratrol supplementation (500 mg daily for 28 days) in healthy humans and found considerable improvements in cognitive performance, cerebral blood flow, subjective sleep, mood, health, and blood pressure. A list of completed and terminated clinical trials in which RSV was tested for metabolic disorders is reported in Table 2. Focusing on completed clinical trials with available results, NCT02114892 evaluated the effect of RSV on metabolic syndrome, demonstrating that, when administered three times per day (1,500 mg/die) before meals, RSV was able to treat and protect from obesity and diabetes with beneficial effects on glucose and lipid metabolism, blood pressure, and body weight. Another phase 1/2 study (NCT02095873) evaluated the effects of a formulation composed of RSV and hesperetin in obese subjects and found that these molecules are dietary inducers of glyxalase 1, improving metabolic and vascular health of obese subjects (Xue et al., 2016).

The flavonoid polyphenol quercetin (Que; 3,3′,4′,5,7-pentahydroxyflavone) is a natural, safe dietary supplement found in a glycoside form in fruits, vegetables, and nuts, which has antioxidant and anti-inflammatory properties (Nabavi et al., 2012; Wu et al., 2014).

In recent years, the scientific community has focused on the potential antiproliferative, chemopreventive and anticarcinogenic activities of Que as well as on its role as a modulator of gene expression. However, Que was also found to have potentially toxic effects including mutagenicity, pro-oxidant activity, mitochondrial toxicity, and inhibition of enzymes involved in hormonal metabolism (Li et al., 2016). Due to its poor solubility, short half-life, and low bioavailability, its medical use is limited (Konrad and Nieman, 2015). In humans, Que bioavailability is very low (~ 2%) and absorption varies from 3% to 17% in subjects receiving 100 mg/die (Costa et al., 2016). Que may reduce infection (Li et al., 2016), hepatic lipemic-oxidative damage (Cui et al., 2013) (Zhang et al., 2016b), and antioxidant risk (Xu et al., 2019). In addition, Que is known to exert a modulating action on immunity (Galleggiante et al., 2019). As regards its mechanism of action, in some cell lines Que was able to inhibit the production of TNF in macrophages (Tang et al., 2019), IL-8 in A549 lung cells induced by lipopolysaccharide (LPS) (Geraets et al., 2007), and TNF-α and IL-1α mRNA levels in glial cells, causing a decrease in neuronal cell death induced by microglial activation (Li et al., 2016). Mainly in immunity and inflammation, Que acts on leukocytes and targets many intracellular signaling kinases and phosphatases as well as enzymes and membrane proteins (Li et al., 2016). The immunostimulating effect of Que is due to induction of the expression of interferon-γ (IFN-γ) derived from Th-1 and inhibition of IL-4 derived from Th-2 in normal peripheral blood mononuclear cells (Nair et al., 2002). In addition, Que reduces T cell proliferation by blocking IL-12-induced tyrosine phosphorylation of JAK2, TYK2, STAT3, and STAT4 (Muthian and Bright, 2004; Nabavi et al., 2012). In inflammation, Que inhibits the enzymes COX and lipoxygenase (Lee and Min, 2013; Savikin et al., 2017). In the RAW 264.7 cell line, Que was also shown to counteract LPS-induced inflammation by phosphorylation of tyrosine phosphatidylinositol-3-kinase (PI3K)-p85 and complex formation of toll-like receptor 4 (TLR4)/MyD88/PI3K (Endale et al., 2013).

Oxidative stress occurs following an imbalance of the body’s antioxidant defence mechanisms and excessive generation of free radicals, and is involved in various pathologies such as diabetes, atherosclerosis, hypertension, neurodegenerative diseases, inflammation, and cancer (Oboh et al., 2016). Que is a powerful ROS scavenger and its antioxidant action is due to the presence of two pharmacophores within the molecular structure, which confer a favorable configuration for free radical elimination (Costa et al., 2016). Generally, Que reduces the effects of free radicals by transferring the hydrogen atom and stabilizing the radicals, a feature that has a structure-function relationship (Oboh et al., 2016).

Que can also act as both an antioxidant and pro-oxidant agent. At low concentrations (10–10 µM), Que displayed a protective effect against oxidative DNA damage (in vitro) in human lymphocytes (Li et al., 2016). At concentrations between 5 µM and 50 µM, Que was able to directly eliminate ROS in vitro (Costa et al., 2016). However, its effect in vivo is very likely not direct but due to its ability to modulate the cell’s antioxidant defense mechanisms; moderate oxidative stress can in fact increase the cell’s antioxidant defenses, resulting in general cytoprotection (Halliwell et al., 2005). Recent research showed that oxidized LDL (oxLDL) induces oxidative stress (Lara-Guzman et al., 2018). Oxidative injuries promote ROS generation in human endothelial cells and SIRT1 regulates endothelial function. Therefore, enhancement of SIRT1 activity and SIRT1/AMPK axis upregulation inhibits oxidative injury, inducing endothelial dysfunction (Chen et al., 2013) (Shentu et al., 2016). Que may reduce oxLDL-induced oxidative damage by upregulating SIRT1 and AMPK (Hung et al., 2015), therefore potentially preventing oxLDL-impaired SIRT1 inhibition linked to endothelial dysfunction. These findings indicate that SIRT1 can function as a regulator to improve AMPK activity under oxLDL stimulation (Hung et al., 2015).

It was very recently shown that Que (70 mg/kg) can reduce insulin resistance and improve glucose metabolism by reducing sensitivity to T2D/insulin resistance in ob/ob mice via SIRT1 activation (Hu et al., 2020). In this context, another study showed that in streptozotocin-induced diabetic rats, Que (100 mg/kg) inhibits oxidative damage by increasing SIRT1 expression and decreasing levels of NF-κB, a SIRT1 substrate (Iskender et al., 2017).

In recent years, the scientific community has focused on the role of apoptosis in cardiovascular disease, showing that oxidative stress, myocardial ischemia, hypoxia, and ischemia/reperfusion injury may induce myocardial apoptosis (Donniacuo et al., 2019). Tang and colleagues evaluated the effects of Que in improving myocardial ischemia/reperfusion injury (MI/R)-induced cell apoptosis both in vitro and in vivo. SIRT1 and PGC-1α expression levels were decreased in rat MI/R groups, but were significantly increased after treatment with Que (Tang et al., 2019). Furthermore, activation of SIRT1/PGC-1α pathway upregulated Bcl-2 expression and downregulated Bax, exerting anti-apoptotic effects. The authors hypothesized that Que might improve MI/R-induced myocardial damage via regulation of SIRT1/PGC-1α and Bcl-2/Bax pathways (Tang et al., 2019). Que is also reported to regulate ROS generation and mitigate mitochondrial dysfunction by promoting their biogenesis. Specifically, in a study to develop a therapeutic strategy for osteoarthritis, Que was shown to increase expression levels of SIRT1, PGC-1α, NRF1 and NFR2, TFAM, and phospho-AMPK α in osteoarthritis rats, confirming the hypothesis that Que might act via the AMPK/SIRT1 signaling pathway (Qiu et al., 2018). Overall, these findings suggest that Que may counteract cardiovascular disease and oxidative damage.

The growing body of evidence supporting the beneficial effects of Que has led to its clinical use, as demonstrated by the number of clinical trials (72 studies on ClinicalTrials.gov). A list of completed studies using Que in different metabolic and inflammatory conditions is reported in Table 3. Specifically, a phase 2 clinical trial (NCT01839344) measured the effect of Que on glucose tolerance and postprandial endothelial function in subjects with T2D compared to the effect of an alpha-glusidase inhibitor, acarbose. The administration of 2 g of Que led to a decrease in postprandial blood glucose (NCT01839344). Given its antioxidative and anti-inflammatory capacities, this flavonoid was considered a good candidate for antioxidant therapy in mucositis (NCT01732393), hepatitis C (NCT01438320), idiopathic pulmonary fibrosis (NCT02874989), osteoporosis (NCT00330096), uric acid metabolism (NCT01881919), cytokine release (NCT01106170), and chronic obstructive pulmonary disease (NCT01708278). In the latter study, Que supplementation was safely tolerated by patients with mild-to-severe chronic obstructive pulmonary disease, opening the way towards the potential use of Que as a therapeutic agent for this condition.

However, as for RSV and nutraceuticals in general, the results of molecular studies on Que obtained from in vitro investigations and animal models are often inconsistent with data from clinical trials. Concentration factor (dose and timing of administration) and bioavailability are the two main issues that require further clarification. Additional studies are needed to identify the optimal concentration of Que for it to exert a beneficial effect, for example on insulin sensitivity.

Berberine (BBR) is an isoquinoline alkaloid reported to have analgesic, anticancer, anti-inflammatory, and myocardial protective properties (Cicero and Baggioni, 2016). It was found to exert protective antioxidative effects in different physiologic and pathologic conditions (Huang et al., 2018; Li et al., 2020b). However, the mechanisms underlying these effects remain unclear. BBR was described as a potential antitumor agent that induces cell cycle arrest in G0/G1 phase, increases Cip/p21 and Kip/p27 protein expression, decreases expression of cyclin D1, D2, and DE, and the cyclin-dependent kinases Cdk2, Cdk4, and Cdk6, promoting apoptosis in HL-60 human leukemia cells (Li et al., 2017). BBR can also deregulate telomerase activity and promote mitochondria-dependent apoptosis in HepG2 human hepatocarcinoma cells through caspase 8 and caspase 3 activation, PARP cleavage induction, increased expression of the pro-apoptotic protein Bax through activation of FOXO transcription factors, and inhibition of Bcl-2 and Bcl-x anti-apoptotic protein expression (Hwang et al., 2006). BBR was observed to exert an apoptotic effect by inducing ROS production and increasing MAPK and JNK activity of p38 in SW620 human colon carcinoma cells, and by increasing Ca⁺ and cytochrome C release in HSC-3 squamous cells (Song et al., 2020). In addition, BBR inhibits the proliferation of cancer cells through an anti-inflammatory pathway. In oral carcinoma cell lines and in SCC-4 cells, BBR inhibits expression of COX2 and AP-1 bond, decreases prostaglandin E2 (PGE2) production, and suppresses NF-κB, IKK, ERK, and JNK activities. Furthermore, BBR can inhibit colon cancer cell growth by activating retinoid X receptor α (RXRα), which binds RXRα, and promoting β-catenin degradation (Ruan et al., 2017). However, some studies highlighted the potential ability of BBR to prevent oxidative stress-induced senescence by activating AMPK and restoring NAD⁺ levels (Song et al., 2020).

Initial research revealed a significant role of SIRT1 signaling in mediating the antioxidant effect of BBR in diabetes (Pang et al., 2015) and in lipid metabolism (Hasanein et al., 2017). The lipid-lowering activity mediated by co-treatment with BBR and RSV was investigated in mice exposed to a high fat diet (Zhu et al., 2018). In vivo data showed that BBR combined with RSV lowered total cholesterol, triglyceride, and LDL cholesterol levels in mice. These findings were also confirmed in vitro with 3T3-L1 adipocytes treated with BBR or RSV alone. Specifically, BBR and RSV co-treatment was able to reduce lipid accumulation more robustly than single treatments. BBR in combination with RSV displayed hypolipidemic effects likely mediated by SIRT1 expression regulation. Moreover, BBR pre-treatment seemed to counteract SIRT1 downregulation (Zhu et al., 2018).

The antioxidant and anti-inflammatory effects of BBR were also investigated in heart (Yu et al., 2016). BBR-mediated SIRT1 activation reduced MI/R injury by affecting oxidative damage and inflammation signaling. Specifically, BBR exerted an antioxidant effect by decreasing the generation of cardiac superoxide and gp91^phox expression, and by increasing SOD levels (Yu et al., 2016). A previous study had also shown that SIRT1 activation promotes antioxidant molecule production and decreases pro-apoptotic proteins through FOXO1 activation, thus protecting against MI/R lesions (Hsu et al., 2010).

As well as activating SIRT1, BBR is also able to decrease FOXO1 acetylation, triggering anti-apoptotic signaling pathways via Bcl-2 expression, and Bax and caspase-3 downregulation (Yu et al., 2016).

A very recent report described the protective effect of BBR against doxorubicin-induced cardiovascular damage (Wu et al., 2019). This effect is mediated by SIRT1/p66Shc pathway (Sampaio et al., 2016). Data obtained in a rat model and in rat H9c2 cardiac cells showed that BBR treatment leads to upregulation of SIRT1 and downregulation of p66shc expression both in vivo and in vitro, resulting in suppression of ROS production, apoptosis, and mitochondrial damage, and improving cardiac dysfunction. This effect did not occur if H9c2 cells were treated with the SIRT1 inhibitor EX-527 (Bai et al., 2018), indicating that BBR action was dependent on SIRT1 (Wu et al., 2019). Another study investigated the beneficial effect of BBR in an in vivo diabetic mouse model and in vitro pancreatic beta cell NIT-1 high glucose treated to induced diabetic condition. BBR attenuated oxidative stress by increasing SOD1 levels through activation of SIRT1 and inhibition of miR-106b expression (Chen and Yang, 2017).

These promising results have paved the way towards the clinical use of BBR. A list of clinical studies investigating the beneficial effects of BBR in inflammatory and metabolic diseases is reported in Table 4. Given the experimental efficacy of the antidiabetic and antidyslipidemia action of BBR, most of the 18 completed or terminated clinical trials focused on these properties. Two clinical trials tested the anti-diabetic effect of BBR in patients with diabetes or diabetes and dyslipidemia (NCT00425009 and NCT00462046). Several clinical studies investigated its effects on hyperlipidemia and hypercholesterolemia and relative disorders. In particular, two phase 4 clinical trials (NCT02422927 and NCT03470376) tested the ability of a nutraceutical combination containing 500 mg BBR to ameliorate inflammation lipid profile and endothelial injury markers in patients with elevated levels of high-sensitivity C-reactive protein and in HIV-infected patients receiving stable antiretroviral therapy. In addition, a phase 2 clinical study (NCT03216811) assessed the efficacy of a nutraceutical compound (3 mg containing fermented red rice) in terms of cholesterol, and endothelial and inflammatory parameters in subjects with hypercholesterolemia and low-to-moderate cardiovascular risk. The findings of a very recent study suggest that BBR may be effective and safe to reduce cardiovascular risk associated with metabolic syndrome (Mercurio et al., 2020).

Curcumin (Cur) or 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (diferuloylmethane) is a natural bioactive polyphenol compound mediating a wide spectrum of biological functions. The molecular structure of Cur consists of two aromatic rings containing phenolic O-methoxy groups linked by a carbon bond, which has a β-unsaturated β-diketone fraction (Priyadarsini, 2014). Thousands of years ago, Indians and Chinese described the health-giving effects of this substance, derived from the turmeric plant (Gupta et al., 2014). Today, Cur is considered a potential agent with antioxidant, anticancer, and anti-inflammatory properties (Yu et al., 2019).

As an antioxidant, Cur is able to eliminate ROS and RNS by increasing the expression of antioxidant proteins via induction of upstream coding genes such as nuclear factor erythroid 2-related factor 2 (Nrf2), kelch-like ECH-associated protein 1 (Keap1), and antioxidant response element (ARE) (Abdelsamia et al., 2019). Nrf2 is a transcription factor involved in cellular stress response. Under normal conditions, the cystine-rich zinc Keap1 metalloprotein binds Nrf2 inside the cytoplasm, promoting ubiquitination and consequent proteasomal degradation and preventing Nrf2 nuclear translocation (Serafini et al., 2019). In contrast, under stress conditions Keap1 activity is inhibited by phosphorylation and free Nrf2 moves to the nucleus, where it binds to ARE in the regulatory regions of cytoprotective proteins and promotes transcription of antioxidant genes such as SOD, glutathione peroxidase (GPx), and GSH, and of phase II detoxifying enzymes such as heme oxygenase-1 (HO-1), glutathione transferases (GST), nicotinamide adenine dinucleotide phosphate (NADPH), and NAD(P)H dehydrogenase [quinone] 1 (NQO1) (Serafini et al., 2019). Cur is able to activate Nrf2/Keap1/ARE signaling pathway by Michael reaction with thiol residues in Keap1, inducing the release and activation of Nrf2 and promoting antioxidant effects (Wafi et al., 2019; Yu et al., 2019).

Cur was also shown to exert immunomodulatory activity by interacting with elements involved in inflammatory response including JAK/STAT pathway, suppressor of cytokine signaling (SOCS) expression, and TLR4/MyD88/NF-κB axis. Cur inhibits phosphorylation of JAK/STAT by binding with its α,β-unsaturated carbonyl portion to residue 259 of cysteine in STAT3 with subsequent activation. It is known that in vitro, even at 7.5 µM concentration, Cur is able to phosphorylate STAT3 and attenuate inflammatory response (Serafini et al., 2019). SOCS is an antagonist of JAK/STAT signaling and is involved in the regulation of inflammatory proteins and cytokines. In vitro, Cur restores expression of SOCS1 and SOCS3, and inhibits expression of IL-6, TNF-α, and PGE2 in RAW 264.7 macrophages (Guimaraes et al., 2013), while in vivo it restores immunological balance by acting on JAK/STAT/SOCS signaling, inhibiting JAK2, STAT3, and STAT6 phosphorylation and increasing SOCS1, SOCS3, and PIAS3 expression (Zhang et al., 2016a). Furthermore, some in vitro and in vivo studies show that Cur can downregulate TLR4, MyD88, and NF-κB signaling at neuronal level by inducing the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), producing an anti-inflammatory effect.

Cur is able to act on apoptosis and on mitochondrial biogenesis and dysfunction through SIRT activation by small molecules (Gupta et al., 2012). Cur can downregulate expression of growth factor receptors, transcription factors, TNFs, and nitric oxide synthase, and increase AMPK levels. In vascular smooth muscle cells, Cur promotes AMPK activation, which enhances superoxide and ATP production. This event stimulates an increase in NAD⁺ levels and SIRT1 activation (Zendedel et al., 2018). Cur-induced SIRT1 upregulation has beneficial effects against a range of diseases including cardiac fibrosis, diabetes, and ischemia/reperfusion injury (Zendedel et al., 2018 #7; Yang et al., 2013 #5). The involvement of mitochondrial oxidative damage in several diseases such as MI/R is well known (Yang et al., 2013). Yang and colleagues investigated SIRT1 action after Cur treatment and the manner in which Cur might attenuate MI/R-induced mitochondrial oxidative damage. In vivo and in vitro experiments on rat heart and cardiomyocytes showed that Cur pre-treatment had protective effects, decreasing myocardial infarct size (Yang et al., 2013). Heart injury and mitochondrial oxidative damage are characterized by ROS overproduction and a reduction in succinate dehydrogenase or COX activity, leading to mitochondrial respiratory chain deficiency (Yang et al., 2013). Cardiomyocytes treated by Cur displayed upregulation of SIRT1, COX, and succinate dehy-drogenase (SDH), and downregulation of Bax. These effects were abolished when cardiomyocytes were treated with SIRT1 siRNA. In these conditions, the levels of decreased SIRT1 abolished the effects of Cur treatment. These findings show that Cur-induced cardio-protection was mediated by SIRT1 (Yang et al., 2013). T2D is a chronic illness requiring continuing care to prevent long-term and acute complications. Cur may have positive effects in T2D by mediating the reduction of NF-κB expression in inflammatory pathway (Zendedel et al., 2018). NF-κB deregulation can influence other mechanisms in which SIRT1 and AMPK are involved, such as glucose absorption in skeletal muscle. Data obtained in diabetic mice models showed that supplementation of Cur for 8 weeks might promote indirect activation of SIRT1 through AMPK (Jimenez-Flores et al., 2014).

Over time, preclinical studies have shown that Cur can act in various human diseases including immunodeficiency, virus infections, rheumatoid arthritis, myocardial infarction, atherosclerosis, and diabetes (Hsu and Cheng, 2007). A phase I study was published for the first time in 2001. Patients were subjected to five different Cur doses (500, 1,000, 2,000, 4,000, and 8,000 mg) every day for 3 months, and data showed that Cur treatment up to 8,000 mg/day is not toxic (Hsu and Cheng, 2007). Another study investigated Cur-mediated effects in patients with chronic non-alcoholic pancreatitis, showing that patients had a strong reversal of lipid peroxidation (Durgaprasad et al., 2005). The development of new routes of administration and new formulations of Cur with better bioavailability could be fundamental for future therapeutic strategies.

A list of completed and terminated clinical trials investigating the effects of Cur in metabolic and inflammatory diseases is reported in Table 5. A phase 2 clinical study (NCT01925547) investigated the effect of Cur micelles on inflammation and lipid metabolism markers in subjects at risk for metabolic syndrome. Two other trials, a phase 2 (NCT02017353) and a phase 3 (NCT02099890) study, investigated the effect of Cur on inflammation induced by endometrial carcinoma and spinal cord injury, respectively. Interesting results from three phase 2/3 clinical studies showed that Cur (as capsules or gel) prevents or reduces radiation-induced dermatitis in breast cancer patients receiving radiotherapy, enhancing the function of normal tissues (NCT01246973, NCT01042938, NCT02556632).

The dietary flavonoid fisetin (3,3′,4,7-tetra-hydroxyflavone) is a natural polyphenol present in plants and fruits such as apples, persimmons, grapes, onions, kiwi, kale, and strawberries, whose daily intake is estimated to be about 0.4 mg (Khan et al., 2013). This human diet constituent is reported to exert some beneficial anticancer, cardiovascular preventive, anti-inflammatory, and antioxidant effects that support normal cell homeostasis and cytoprotection (Chen et al., 2015; Kim et al., 2015). Fisetin was shown to have neuroprotective activity in various Huntington’s disease models through ERK activation and to inhibit melanoma growth by suppressing Akt/mTOR1 pathway (Sechi et al., 2018). A recent study reported that fisetin reduces myocardial tissue damage in a reperfusion ischemia model by suppressing mitochondrial oxidative stress and inhibiting glycogen synthase kinase 3β (Shanmugam et al., 2018). As a polyphenol, fisetin can counteract oxidative stress and mediate immune response via AMPK/SIRT1 and Nfr2 pathways (see Figure 1). Fisetin was shown to increase SIRT1 expression and enhance SIRT1-mediated PPAR and FOXO1 deacetylation in 3T3L1 cells (Kim et al., 2015). Specifically, fisetin enhanced the association between SIRT1 and the PPARγ promoter, leading to a block of its transcriptional activity, adipogenesis, and lipid accumulation (Kim et al., 2015). Lipid accumulation is a common feature in NAFLD (Liou et al., 2018). Increased fatty acid synthesis and hepatocyte accumulation is associated with metabolic disorder (Liou et al., 2018). Fisetin treatment in NAFLD mice reduced epididymal adipose tissue, hepatocyte steatosis, and fatty acid synthesis. The data reported by Liou et al. showed an increase in AMPKα phosphorylation and SIRT1 expression levels, while in vitro results revealed a reduction in lipid accumulation and an increase in lipolysis. The beneficial effects of fisetin were also linked to its action as a caloric restriction mimetic (CRM) (Singh et al., 2018). Natural compounds such as metformin and resveratrol display the ability to mimic the effects of caloric restriction, acting on stress response and metabolic pathways (Ingram et al., 2006). A recent study investigated the neuroprotective effects of fisetin as a possible CRM against apoptosis, oxidative stress, aging, and neurodegeneration (Singh et al., 2018). The authors showed that aging of rat brain induced an increase in pro-inflammatory cytokines and that treatment with CRMs such as metformin can reduce inflammation (Singh et al., 2019). In an attempt to demonstrate that fisetin could have beneficial effects against neuro-inflammation comparable to metformin, Singh et al. showed that fisetin mediated protective effects via SIRT1 activation, enhancing NF-κB deacetylation and promoting inhibition of pro-inflammatory gene expression (Singh et al., 2019). Data suggested that fisetin may be a suitable therapeutic candidate for aging and neurological diseases.

However, there are only six currently available clinical trials using fisetin, most of which are still recruiting (Table 6). These pilot studies aim to test the anti-inflammatory efficacy of fisetin in Frail Elderly Syndrome (NCT03675724 and NCT03430037) and in symptomatic knee osteoarthritis patients (NCT04210986). Another phase 2 clinical study (NCT03325322) intends to evaluate the effects of oral fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, inflammation, and physical function in subjects with chronic kidney diseases and diabetes.